## Precision Medicine Initiative (PMI) Committee Meeting


July 26, 2023



## Agenda

- Role Call
- Project Status Updates
- Cohort Migration Workflow Presentation
- Project Discussion Items
- Review FAQs
- Next Steps

## **Stakeholder Representation**



## **Project Status Updates**



## **Project Updates**

PMI Project Deliverable	Target Release Date	Release Vehicle
ComboMATCH changes (Disease fields, histology, behavior field code)	Released: July 17, 2023	Screening Protocol EC Template v2.0
Designated Labs for Combo	July 31, 2023	Screening Protocol EC Template v3.0
Re-Screening ComboMATCH	August 18, 2023	Screening Protocol Re-Screening EC Template v1.0
MyeloMATCH Tx Protocol Crossover (for S01, CTG01 and EA02)	October 3, 2023	Part of the existing Treatment Protocol workflow.
Cohort Migration	September 25, 2023	Treatment Protocol Cohort Migration EC Template v1.0
Re-Screening MM	Oct 10, 2023	Screening Protocol Re-Screening EC Template v2.0
STMF	Oct 16, 2023	PMI Screening Protocol ALS v2.0
CLIA	Oct 16, 2023	PMI Screening Protocol ALS v2.0
Path	Oct 16, 2023	PMI Screening Protocol ALS v2.0
PMI Screening Protocol ALS v2.0	~ mid-October 2023	Target to start Group Beta UAT
MyeloMATCH Stratification	Oct 20, 2023	Part of existing Treatment Protocol Workflow

## EC Screening Template Release Schedule

#### SWOG Question: Does SWOG need to continue study build activities on ALSv1.0 or wait until ALSv2.0.

NCI Leadership is reviewing the options and will provide an update via email by next week.

Release	Details	Tentative Release Date
V1.0	Production Release	February 15 <sup>th</sup> 2023
V2.0	Includes CM changes (Disease fields, histology, behavior field code)	July 17 <sup>th</sup> 2023
V3.0	Includes updates for Designated Labs (DLAP fields)	August 18 <sup>th</sup> 2023
V4.0	MM MSRP changes (Provisional Diagnosis Question)	TBD

## **PMI Form Mappings**

Group	Status Update
Alliance	Pending, finalization & meetings scheduled with NCI Leadership for week of 08/1/2023.
COG	Pending finalization.

## Group Roadblocks

Group	7/12/2023	7/26/2023
ECOG- ACRIN	Need the EC template	
SWOG	Need v4 to complete study build for MM	<ul> <li>Need v4 to complete study build for MM</li> <li>Need confirmation and timeline on ineligible process</li> </ul>
NRG	Need more information on the OPEN process; will walk through the Cohort Migration workflow	No questions
Alliance	<ul> <li>Waiting for Cohort Migration Template – Is there anything the project team to provide to help prepare. Knowing what the variables arewill add that to next presentation</li> </ul>	No questions
ССТС	<ul> <li>EC v2 template; keeping MSRP on hold</li> <li>Need patients for UAT testing</li> </ul>	No questions
COG	No roadblocks	<ul><li>No updates;</li><li>Waiting on mappings</li></ul>

## **Cohort Migration Workflow Presentation**

#### Cohort Migration & pending Fact Sheet details

DRAFT PMI CDISC Treatment Protocol Cohort Migration EC Template Fact Sheet

III. CDE Requirements for <u>PMI Treatment Protocol Cohort Migration</u> EC Forms/Worksheets (caDSR II Form PID *tbd*):

PMI Treatment Protocol Cohort Migration CDE Requirements							
PMI EC CDE PID	PMI EC QT/Prompt	Combo MATCH	Myelo MATCH	OPEN Widget Type	Notes		
Treatment	Protocol Module 1						
6380045	Screening protocol ID	Conditional*	Optional	Edit Box	Groups should designate this module to the "Pre-Requisite" screen under the OPEN Questions screen. These fields will be (1) validated against the data on the CTSU Demography Standard Form, (2) are required for successful transactions for the PMI CDISC Off		
6380049	Screening participant ID	Conditional*	Optional	Edit Box	Treatment (OT) and PMI CDISC Consent Withdrawal (CW) Forms, and (3) used to validate patient enrollment in OPEN to the correct treatment protocol per treatment assignment from MATCHBox.		
Treatment	Protocol Module 2						
10987207	Cohort migration assignment	Conditional*	Optional	tbd	This field will specify the Cohort Migration details for a patient. <u>Instructional Text for OPEN Screen</u> : "Patients receiving the control drug who experience disease progression may elect to migrate to another cohort and receive combination treatment. Click 'Request' to see if the patient is eligible; click 'Cancel' to withdraw a request."		

\*Use of this form conditional/protocol-specific for ComboMATCH; if said ComboMATCH protocol includes cohort migration, then this form and the corresponding fields are required required.

## **PMI Project Discussion Items**

## **OPEN** Notification

- During testing, ECOG-ACRIN raised (on a PMI called back in February) that they did not have visibility into whether they
  successfully registered a participant in OPEN or if registration failed.
- The ComboMATCHBox team has just completed a ticket for notifying ECOG-ACRIN of successful/unsuccessful registration. Who at ECOG-ACRIN would need to receive the notifications/what email addresses need to be added to the distribution list?



## Next Steps





## Next meeting will be on 8/9/2023 at 1:00pm EST

## Agenda

- Role Call
- Project Status Update
- Group Status Update
- Review FAQs

## Communication



#### Contact the PMI Mailbox for any PMI related questions & comments

#### pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

# 

#### PMI Wiki

#### https://wiki.nci.nih.gov/display/CDISC/Precision+M edicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki




www.cancer.gov/espanol

www.cancer.gov

## Appendix



#### **Target Timeline**



#### Target Timeline

Jan 31, 2023	<ul> <li>NCI Activities</li> <li>Release EC Template v1</li> <li>Release Prod Screening Protocol ALS</li> <li>Release Prod Treatment Protocol ALS</li> <li>Release Prod Central Study ALS</li> <li>Release NCI OPEN Integrations for Prod</li> <li>Release NCI Genexus Installation (MyeloMATCH)</li> </ul>
Jan 31 to Feb 14, 2023	NCI + Group Activities - Support Group Study Builds
Feb 14,	NCI + Group Activities
2023	- Launch BOTH Initiatives
Spring	NCI Activities
2023	- Release Additional ALS(s)

#### ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps / ' '	
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	NRG 8/15/2022 Revision 4 back from CIRB with Approval on Hold funding sheet and IND filing.		<ul> <li>(P) Olaparib (AZD2281) (747856)</li> <li>(O) Selumetinib</li> <li>(AZD6244 hydrogen sulfate) (748727)</li> </ul>
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane- Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

#### ComboMATCH Priority 2 List

Stu #	dy Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	10/24. CTEP currently reviewing stips.	<ul> <li>(P) Binimetinib (788187)</li> <li>(O) OXALIplatin</li> <li>(Eloxatin) (266046)</li> <li>(O) 5-Fluorouracil (5-FU)</li> <li>(19893)</li> <li>(O)Leucovorin calcium</li> <li>(3590)</li> </ul>
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD- 0332991) (772256) (O) Binimetinib (788187)

#### ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	<ul> <li>(P) Selumetinib</li> <li>(AZD6244 hydrogen sulfate) (748727)</li> <li>(O) DAY101 (TAK-580, MLN-2480) (800798)</li> </ul>
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD- 0332991) (772256)

#### MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol


#### MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM10A-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS- EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

### **Review Schemas**




#### EAY191-N4




#### EAY191-E4



#### EAY191-N2- Draft



#### EAY191-S3



N = 33


#### MMIYA-CTG01 Draft

#### Protocol MM1YA-CTG01

People who have Acute Myeloid Leukemia in the intermediate risk ELN category

#### **Excludes People with:**

- · isolated myeloid sarcoma
- prior therapy for AML (except for hydroxyurea and leukapheresis to control blood counts)
- the following categories of AML:
- Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion 16(p13.1;q22), t(16;16)(p13.1;q22);CBFB-MYH11
- CEBPA biallelic mutations
- NPM1 mutation
- AML with PML-RAR
- AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1, 11q23/KMT2 rearrangements
- AML with FLT3-ITD or FLT3-TKD mutations
- Therapy related AML, or AML following a diagnosis of myelodysplasia or myeloproliferative neoplasm



#### N = 153

